Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans

Clinical and Vaccine Immunology

Volumn 19, Issue 11, 2012, Pages 1792-1797

  Ledgerwood, J E ^a   Hu, Z ^b   Gordon, I J ^a   Yamshchikov, G ^a   Enama, M E ^a   Plummer, S ^a   Bailer, R ^a   Pearce, M B ^c   Tumpey, T M ^c   Koup, R A ^a   Mascola, J R ^a   Nabel, G J ^a   Graham, B S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; UNCLASSIFIED DRUG; VRC AVIDNA036 00 VP;

ANTIBODY RESPONSE; ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTRACELLULAR CYTOKINE STAINING ASSAY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERODIAGNOSIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, VIRAL; CYTOKINES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PLACEBOS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; YOUNG ADULT;

EID: 84868217771     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05663-11     Document Type: Article

References (22)

1. Belshe RB. 2005. The origins of pandemic influenza: lessons from the 1918 virus. N. Engl. J. Med. 353:2209-2211. (Pubitemid 41697281)
2. Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. 2010. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin. Ther. 32:2186-2197.
3. Brady RC, et al. 2009. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 27:5091-5095.
4. Bresson JL, et al. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664.
5. Catanzaro AT, et al. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replicationdefective recombinant adenovirus vector. J. Infect. Dis. 194:1638-1649. (Pubitemid 44901994)
6. Catanzaro AT, et al. 2007. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25:4085-4092. (Pubitemid 46616987)
7. Goji NA, et al. 2008. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J. Infect. Dis. 198:635-641.
8. Laddy DJ, et al. 2009. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83:4624-4630.
9. Ledgerwood JE, et al. 2011. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J. Infect. Dis. 203:1396-1404.
10. Ledgerwood JE, et al. 2011. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11:916-924.
11. Lopez P, et al. 2011. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J. Infect. Dis. 203:1719-1728.
12. Martin JE, et al. 2008. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine 26:6338-6343.
13. Martin JE, et al. 2007. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196:1732-1740. (Pubitemid 351411932)
14. Martin JE, et al. 2006. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccine Immunol. 13:1267-1277. (Pubitemid 46768881)
15. Patel A, et al. 2009. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 27:3083-3089.
16. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35:69-75. (Pubitemid 9096975)
17. Sambhara S, Poland GA. 2006. Avian influenza vaccines: what's all the flap? Lancet 367:1636-1638. (Pubitemid 43728236)
18. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. 2004. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 103:91-95. (Pubitemid 38649066)
19. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
20. Wei C-J, et al. 2010. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci. Translational Med. 2:24ra21.
21. Wei CJ, et al. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064.
22. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. 2008. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J. Infect. Dis. 197:580-583. (Pubitemid 351321536)